Question follow-through · 32758
Vitiligo: Medical Treatments
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure patients with vitiligo have access to effective treatments in the context of NICE's decision not to recommend Ruxolitinib for NHS use.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 21 Feb 2025
- Target answer date
- 25 Feb 2025
- Answer
- 26 Feb 2025 · 5 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
21 Feb 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure patients with vitiligo have access to effective treatments in the context of NICE's decision not to recommend Ruxolitinib for NHS use.
25 Feb 2025
Target answer date
Date supplied by the official written-questions record.
26 Feb 2025
Answer published
The Government wants National Health Service patients to be able to benefit from access to clinically and cost-effective new treatments, and the National Institute for Health and Care Excellence (NICE) makes recommendations for the NHS on whether new medi...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.